Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus treatment
The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs. Its path to relevance didn’t begin until Robert Jordan plucked it from mothballs.
A Gilead scientist at the time, Jordan convinced the company seven years ago to let him assemble a library of 1,000 castoff molecules in a search for medicines to treat emerging viruses. Many viral illnesses threaten human health but don’t attract commercial interest because they lack potential for huge drug sales.
“I kept asking them, ‘Is this okay?’ ” said Jordan, who is now a vice president at a pharmaceutical start-up. “These don’t represent a commercial opportunity but a public health opportunity. Gilead gave me their blessing to do this on the side.” Continue reading.